10 Frameworks for Pharma Teams Who Need Verified Data, Not Estimates
PSP programmes can't prove adherence. Sustainability teams can't quantify device recovery. CFOs are paying EPR fees with nothing to show regulators. These frameworks build the evidence layer all three need.
PSP budgets are under pressure.
Self-reported compliance won't survive scrutiny.
Your adherence data has a credibility problem
Most PSP programmes report on enrolled patients, not verified ones. Payers, HTA bodies, and regulators are increasingly demanding field-level evidence that holds up under audit.
Medical device EPR obligations are tightening
Inhalers and injection pens have a documented end-of-life problem. Without a verified return scheme, pharma companies face growing EPR exposure, and no way to demonstrate compliance.
Outcomes-based contracts require outcomes data
Value-based agreements with payers require verified adherence. A self-reported adherence rate from a patient diary is not the same as a photo-confirmed, geo-validated dose record.
The pharmacy network is already there
Every pharma company has existing pharmacy and HCP relationships. The verified data collection layer is sitting idle. No app to distribute. No hardware to install. Just a link.
Available Now
Operational playbooks for pharma PSP and ESG teams, built from real deployments, not whitepaper theory.
The Pharma Scope 3 Problem Nobody Talks About
Pharma's Scope 3 emissions include every inhaler, pen, and device that ends up in general waste. This framework maps the hidden exposure, and the verified return model that turns a liability into auditable EPR data.
Why Medical Device Return Programs Fail
Most return schemes collect less than 5% of eligible devices. This framework maps the exact leak points and shows the fix: patient friction, pharmacy with no collection mandate, no rep integration.